Julie Decock | Hamad Bin Khalifa University
Hamad Bin Khalifa University


Dr. Julie Decock

Dr. Julie Decock (PhD)

Transitional Cancer and Immunity Center
Qatar Biomedical Research Institute QBRI

Joint Assistant Professor
College of Health and Life Sciences

  • Phone+974-4454-6894


Dr. Julie Decock received her Master of Science (MSc) in Biomedical Sciences from the Free University of Brussels (VUB, Belgium) and completed her Doctor of Philosophy (PhD) in Medical Sciences at the Catholic University of Leuven, KULeuven, Belgium. 

During her PhD she co-founded the breast cancer biobank at the University Hospital of Leuven, Belgium. 

She joined Qatar Biomedical Research Institute (QBRI), in 2013 as a postdoctoral researcher and established the cancer-immune ecosystem group in 2016. In addition, she holds an assistant professor position at HBKU’s College of Health and Life Sciences (CHLS).


Research Interests

  • Tumor-derived and circulating immune-related biomarkers in breast cancer
  • The role of cancer testis antigens within the tumor-immune ecosystem
  • Therapeutic potential of targeting cancer testis antigens for precision medicine in breast cancer
  • Genetic determinants of non-BRCA high-risk familial breast cancer


Scientist, Cancer Research Center

Qatar Biomedical Research Institute (QBRI), Qatar.

2016 - present
  • Joint Assistant Professor

    College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Doha, Qatar.

    2016 - present
  • Postdoctoral Researcher

    Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Qatar.

    2013 - 2016
  • Postdoctoral Researcher

    School of Biological Sciences, Faculty of Science, University of East Anglia (UEA), UK.

    2008 - 2013



Faculty of Medicine, Catholic University of Leuven (KULeuven), Belgium

  • MSc in Biomedical Sciences

    Free University of Brussels (VUB), Belgium


Selected Publications

  • Roelands J, Mall R, Almeer H, Thomas R, Mohamed MG, Bedri S, Bujassoum S, Junejo K, Ziv E, Sayaman RW, Kuppen PJK, Bedognetti D, Hendrickx W, Decock J*

    Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab and European ancestry. Npj Breast Cancer, in press.

  • Naik A and Decock J*

    Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Front. Oncol., doi:10.3389/fonc.2020.598626.

  • Thomas R, Shaath H, Naik A, Toor SM, Elkord E, Decock J*

    Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. Cancer Immunol Immunother. 2020 Jan 13. doi: 10.1007/s00262-020-02480-4.

  • Naik A, Monjazeb AM and Decock J*

    The obesity paradox in cancer, tumor immunology and immunotherapy: Focus on triple negative breast cancer. Front. Immunol. 10:1940. doi: 10.3389/fimmu.2019.01940. Review.

  • Al-Khadairi G, Decock J*

    Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers (Basel). 2019 Jul 15; 11(7). Review.

  • Al-Khadairi G, Naik A, Thomas R, Al-Sulaiti B, Rizly S, Decock J*

    PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med. 17(1):9. doi: 10.1186/s12967-018-1757-3.

  • Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J*

    NY-ESO-1 based immunotherapy of cancer: current perspectives. Front. Immunol. 9:947. doi: 10.3389/fimmu.2018.00947. Review.